MedX Announces Debt Settlement Agreement

Logo
Dec. 22, 2020 23:30 UTC

 

 
 

MISSISSAUGA, Ontario--(BUSINESS WIRE)-- MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that the Company has agreed to settle an amount of $65,000 owing to a professional advisor, subject to all relevant consents and approvals, by issuing 500,000 common shares to the vendor, at a price of $0.13 per share. Regulatory and other consents will include acceptance from the TSX Venture Exchange.

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Turkey and Brazil. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.

Contacts

Rob von der Porten, Chairman and Acting CEO
MedX Health Corp
vonderporten@medxhealth.com

 
 

Source: MedX Health Corp.

Back to news